Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54

Benzinga · 2d ago
Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $66 to $54.